Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer
Recommended Citation
Kandagatla P, Rizk NN, Dokic D, Kochkodan J, Estevez S, Yanik M, Goranta S, Huber-Keener K, and Jeruss JS. Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer. Breast J 2019.
Document Type
Article
Publication Date
9-20-2019
Publication Title
The breast journal
Abstract
We sought to identify factors associated with disparities in tamoxifen utilization among young patients at high-risk for developing breast cancer. We identified 67 premenopausal, high-risk women age 35-45, without surgical prophylaxis, who did not initiate tamoxifen. Factors associated with noninitiation were examined. About 37% of patients had no documented provider-based discussion regarding initiation. Type of high-risk diagnosis was the only factor associated with a provider-based discussion (P = .03). For patients offered tamoxifen, primary reasons for noninitiation were perceived minimal benefit (66.7%), fertility concerns (16.7%), and concerns about side effects (7.1%). Implementation of comprehensive educational strategies regarding the benefits of tamoxifen should be facilitated to improve initiation among young high-risk patients.
Medical Subject Headings
Adult; Antineoplastic Agents; Hormonal/adverse effects; Breast Neoplasms/drug therapy; Female; Humans; Middle Aged; Premenopause; Tamoxifen/adverse effects; chemoprevention; shared decision making; tamoxifen
PubMed ID
31538708
ePublication
ePub ahead of print
Volume
26
Issue
3
First Page
464
Last Page
468
